COSTA MESA, Calif.--(BUSINESS WIRE)--Synthetic Blood International, Inc. (OTCBB:SYBD) today announced that it has named six new members to its Scientific Advisory Board (SAB) to support continued development of Oxycyte™, the Company’s proprietary perfluorocarbon (PFC) therapeutic oxygen carrier and blood substitute.
